Chronos Archive seal
The Human Record

Nelson Mandela

Case HR-ML021-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
18 July 1918 – 5 December 2013
Synthetic DOB
1918-07-18
Index visit
2001-03-10 at age 82
Synthetic MRN
HR-ML021-SYN-TD

Teaching objective: Localized prostate cancer found by a rising PSA in a fit man of 82, on the NCCN prostate guideline, the AUA/ASTRO 1997 localized prostate cancer guideline, and the CMID prostate cancer monograph: risk grouping and staging (unfavorable intermediate risk, with PSMA PET); shared decision-making among observation, radiotherapy with short-term androgen deprivation, and surgery, with life expectancy and an earlier prostate operation weighed; six months of androgen deprivation with radiotherapy, and the monitoring it needs (testosterone, bone density and vitamin D, glucose and lipids, blood pressure, hot flashes, mood, and cognition); urinary and bowel effects of radiotherapy; and PSA surveillance after radiotherapy with the Phoenix definition of recurrence. His doctors' public account, a slight PSA rise on monitoring, a biopsy, hormone therapy, and a seven-week course of curative radiotherapy, frames the episode.

Historical timeline

DateEventClaims
18 July 1918Born in Mvezo, Eastern Cape.CLM-0001
12 June 1964Sentenced to life imprisonment after the Rivonia Trial.CLM-0002
1985Prostate surgery for an enlarged gland while imprisoned.CLM-0003
12 August 1988Taken to hospital and diagnosed with tuberculosis.CLM-0004
11 February 1990Released from Victor Verster Prison.CLM-0002
10 May 1994Inaugurated as president of South Africa.CLM-0009
November 2000A raised PSA level is found on routine monitoring; a later biopsy shows microscopic prostate cancer.CLM-0005
July 24, 2001Diagnosis announced; a seven-week course of curative radiotherapy begins after hormonal treatment.CLM-0006
August 2001His office announces that radiation treatment will continue after a review of the options.CLM-0007
2002Announces that his doctors have cleared him of prostate cancer.CLM-0008
5 December 2013Died at his home in Johannesburg.CLM-0010

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Nelson Rolihlahla Mandela was born in Mvezo, in the Eastern Cape, on 18 July 1918. confirmed Biography of Nelson Mandela supports
D Mandela was convicted with seven co-accused in the Rivonia Trial on 11 June 1964 and sentenced to life imprisonment the next day. He was held on Robben Island, moved to Pollsmoor Prison on 31 March 1982 and to Victor Verster Prison near Paarl on 7 December 1988, and was released from Victor Verster on 11 February 1990. confirmed Biography of Nelson Mandela supports
D In 1985 Mandela had prostate surgery while imprisoned. His urologist said in July 2001 that the gland had been enlarged and was causing a urinary blockage, and that part of it was removed.
An operation for benign prostatic enlargement long before the cancer; the type of operation was not made public. Reports differ on the year and on how much of the gland was removed.
confirmed Biography of Nelson Mandela supports
Mandela's prostate cancer not terminal, doctor says supports
Early prostate cancer is curable (archived copy) context
D Mandela was taken to hospital on 12 August 1988 and diagnosed with tuberculosis; public reports describe it as early tuberculosis, treated at the Constantiaberg Medi-clinic, after which he was moved to Victor Verster Prison.
Pulmonary tuberculosis treated in the past; recorded as personal history.
confirmed Biography of Nelson Mandela supports
Illnesses Madiba has suffered supports
D His doctors said publicly in 2001 that he had been monitored regularly with the prostate-specific antigen (PSA) test, that a slight rise in the PSA led to a biopsy of the prostate, and that the biopsy confirmed microscopic cancer within the gland. News reports said the raised blood level was first found in November 2000.
A PSA rise found on monitoring, with biopsy-proven localized prostate cancer. No PSA value, Gleason score, or stage was made public.
confirmed Early prostate cancer is curable (archived copy) supports
Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) supports
Mandela begins radiation therapy supports
D His spokeswoman said in July 2001 that the cancer was not of a high grade and should not shorten his life span. He received hormonal treatment (anti-androgens) for a while and then began a seven-week course of radiotherapy with curative intent, limited to the prostate, on July 24, 2001; no surgery or chemotherapy was needed. His urologist called it a very early cancer that should be cured.
Localized, not high-grade prostate cancer treated with hormone therapy and curative radiotherapy, as his doctors and spokeswoman described it.
confirmed Early prostate cancer is curable (archived copy) supports
Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) supports
Mandela begins radiation therapy supports
Mandela's prostate cancer not terminal, doctor says supports
D In August 2001 his office said he would continue radiation treatment after a review of the options by two physicians, a radiotherapist, and five urologists, who considered the size and grade of the tumour, the radiological tests, and his response to hormonal treatment; his office said his general health remained good.
The treatment decision as his office announced it.
confirmed Mandela to continue radiation treatment supports
D In 2002 Mandela announced that his doctors had cleared him of prostate cancer.
Recorded as he announced it; no later result was made public and none is used.
confirmed Illnesses Madiba has suffered supports
D Mandela was inaugurated as South Africa's first democratically elected president on 10 May 1994 and stepped down in 1999 after one term. confirmed Biography of Nelson Mandela supports
D Mandela died at his home in Johannesburg on 5 December 2013.
Recorded as a fact; no detail of his last years is used.
confirmed Biography of Nelson Mandela supports
Nelson Mandela timeline 2000-2014 supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer active confirmed both_with_link CLM-0005, CLM-0006, CLM-0007
S Hormone-sensitive prostate cancer active confirmed active CLM-0005, CLM-0006
S Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition active confirmed active CLM-0005, CLM-0006
S History of pulmonary tuberculosis, treated, with no symptoms since resolved confirmed historical CLM-0004
S Personal history of external beam radiotherapy to the prostate active confirmed active CLM-0005, CLM-0006

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2001-03-10 Prostate specific Ag [Mass/volume] in Serum or Plasma 6.4 ng/mL (high)
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 2001-03-10 Testosterone [Mass/volume] in Serum or Plasma 412 ng/dL
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 2001-03-10 Hemoglobin [Mass/volume] in Blood 14.1 g/dL
Reference 13.2-16.6 g/dL
http://loinc.org · 718-7
S 2001-03-10 Leukocytes [#/volume] in Blood by Automated count 5.8 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 2001-03-10 Platelets [#/volume] in Blood by Automated count 226 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 2001-03-10 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2001-03-10 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2001-03-10 Glucose [Mass/volume] in Serum or Plasma 94 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 2001-03-10 Creatinine [Mass/volume] in Serum or Plasma 1.08 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2001-03-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1996)/1.73 sq M 69 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2001-03-10 Calcium [Mass/volume] in Serum or Plasma 9.4 mg/dL
Reference 8.6-10.3 mg/dL
http://loinc.org · 17861-6
S 2001-03-10 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2001-03-10 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 U/L
Reference 40-129 U/L
http://loinc.org · 6768-6
S 2001-03-10 Albumin [Mass/volume] in Serum or Plasma 4.1 g/dL
Reference 3.5-5 g/dL
http://loinc.org · 1751-7
S 2001-03-10 Hemoglobin A1c/Hemoglobin.total in Blood 5.5%
Reference <=5.6%
http://loinc.org · 4548-4
S 2001-03-10 Cholesterol [Mass/volume] in Serum or Plasma 184 mg/dL
Reference <=200 mg/dL
http://loinc.org · 2093-3
S 2001-03-10 Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 mg/dL
Reference >=40 mg/dL
http://loinc.org · 2085-9
S 2001-03-10 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 mg/dL
Reference <=129 mg/dL
http://loinc.org · 13457-7
S 2001-03-10 Triglyceride [Mass/volume] in Serum or Plasma 98 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2001-03-10 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 26 ng/mL (low)
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2001-03-10 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 2001-03-10 International Prostate Symptom Score [IPSS] 7 http://loinc.org · 80976-4
S 2001-04-14 DXA Femur [T-score] Bone density -1.4 (low)
Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis
http://loinc.org · 38263-0
S 2001-04-14 DXA Lumbar spine [T-score] Bone density -0.6
Reference -1.0 or higher is normal; -2.5 or lower is osteoporosis
http://loinc.org · 38267-1
S 2001-04-14 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2001-07-14 Prostate specific Ag [Mass/volume] in Serum or Plasma 0.9 ng/mL
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 2001-07-14 Testosterone [Mass/volume] in Serum or Plasma 18 ng/dL (low)
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 2001-07-14 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference 30-100 ng/mL
http://loinc.org · 62292-8
S 2001-07-14 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 2001-10-27 Prostate specific Ag [Mass/volume] in Serum or Plasma 0.4 ng/mL
Reference <=4 ng/mL
http://loinc.org · 2857-1
S 2001-10-27 Testosterone [Mass/volume] in Serum or Plasma 38 ng/dL (low)
Reference 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation
http://loinc.org · 2986-8
S 2001-10-27 International Prostate Symptom Score [IPSS] 12 http://loinc.org · 80976-4
S 2001-10-27 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2001-06-09 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2001-06-09 Total score [Mini-Cog] 5 http://loinc.org · 72233-0
S 2001-06-09 Total score [AUDIT-C] 0 http://loinc.org · 75626-2

Synthetic vital signs

DateMeasureResultLOINCGrade
2001-03-10Body height183 cm8302-2S
2001-03-10Body weight80.2 kg29463-7S
2001-03-10Body mass index (BMI) [Ratio]23.9 kg/m239156-5S
2001-03-10Systolic blood pressure132 mm[Hg]8480-6S
2001-03-10Diastolic blood pressure78 mm[Hg]8462-4S
2001-03-10Heart rate68 /min8867-4S
2001-03-10Respiratory rate14 /min9279-1S
2001-03-10Body temperature36.6 Cel8310-5S
2001-03-10Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2001-04-14Body height183 cm8302-2S
2001-04-14Body weight80.4 kg29463-7S
2001-04-14Body mass index (BMI) [Ratio]24 kg/m239156-5S
2001-04-14Systolic blood pressure130 mm[Hg]8480-6S
2001-04-14Diastolic blood pressure76 mm[Hg]8462-4S
2001-04-14Heart rate66 /min8867-4S
2001-04-14Respiratory rate14 /min9279-1S
2001-04-14Body temperature36.7 Cel8310-5S
2001-04-14Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2001-07-14Body height183 cm8302-2S
2001-07-14Body weight81.6 kg29463-7S
2001-07-14Body mass index (BMI) [Ratio]24.4 kg/m239156-5S
2001-07-14Systolic blood pressure134 mm[Hg]8480-6S
2001-07-14Diastolic blood pressure78 mm[Hg]8462-4S
2001-07-14Heart rate70 /min8867-4S
2001-07-14Respiratory rate14 /min9279-1S
2001-07-14Body temperature36.6 Cel8310-5S
2001-07-14Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
2001-10-27Body height183 cm8302-2S
2001-10-27Body weight81.4 kg29463-7S
2001-10-27Body mass index (BMI) [Ratio]24.3 kg/m239156-5S
2001-10-27Systolic blood pressure128 mm[Hg]8480-6S
2001-10-27Diastolic blood pressure74 mm[Hg]8462-4S
2001-10-27Heart rate68 /min8867-4S
2001-10-27Respiratory rate14 /min9279-1S
2001-10-27Body temperature36.7 Cel8310-5S
2001-10-27Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2001-06-09Body height183 cm8302-2S
2001-06-09Body weight81 kg29463-7S
2001-06-09Body mass index (BMI) [Ratio]24.2 kg/m239156-5S
2001-06-09Systolic blood pressure132 mm[Hg]8480-6S
2001-06-09Diastolic blood pressure76 mm[Hg]8462-4S
2001-06-09Heart rate68 /min8867-4S
2001-06-09Respiratory rate14 /min9279-1S
2001-06-09Body temperature36.6 Cel8310-5S
2001-06-09Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
Reach an informed, shared decision on treatment after hearing every reasonable option, including observation2001-04-14completedRadiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation
Complete six months of androgen deprivation and the course of radiotherapy with side effects managed2001-10-27completedTwo leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managed
Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise2001-07-14completedFemoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily
PSA falling after radiotherapy, with a written surveillance plan2001-10-27completedPSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months planned

Interventions

InterventionStatusGuideline
Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivationcompletedGL-AUA-ASTRO-PCA-2022-I, GL-NCCN-PROSTATE-2026
Staging for unfavorable intermediate-risk disease with PSMA PET/CTcompletedGL-NCCN-PROSTATE-2026, GL-CMID-2026
Treatment chosen through shared decision-making: image-guided external beam radiotherapy to the prostate with six months of androgen deprivation (leuprolide, with bicalutamide for the first four weeks)completedGL-AUA-ASTRO-PCA-2022-I, GL-AUA-ASTRO-PCA-2022-III, GL-NCCN-PROSTATE-2026
Androgen deprivation monitoring: testosterone, PSA, blood pressure, glucose and lipids, DXA at baseline and every one to two years, vitamin D and calcium, hot flashes, mood, and cognitioncompletedGL-CMID-2026, GL-ACS-PCA-SURV-2014
After radiotherapy: PSA every six months for five years, then yearly, with recurrence defined as a rise of 2 ng/mL above the nadir (Phoenix); urinary and bowel symptoms at every visitcompletedGL-CMID-2026, GL-NCCN-PROSTATE-2026, GL-ACS-PCA-SURV-2014
Distress screening at each visit, physical activity, and a written survivorship care plancompletedGL-ACS-PCA-SURV-2014, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Biography of Nelson Mandela Nelson Mandela Foundation biography
SRC-0002 Early prostate cancer is curable (archived copy) Health24 other
SRC-0003 Former South African President Nelson Mandela diagnosed with prostate cancer (Associated Press) News On 6 other
SRC-0004 Mandela begins radiation therapy Irish Examiner other
SRC-0005 Mandela's prostate cancer not terminal, doctor says The Globe and Mail other
SRC-0006 Mandela to continue radiation treatment Mail & Guardian other
SRC-0007 Illnesses Madiba has suffered SABC News other
SRC-0008 Nelson Mandela timeline 2000-2014 South African History Online other
SRC-0009 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the risk grouping, the choice of six months of androgen deprivation and conventional fractionation at 82, and the androgen deprivation monitoring.
provenance reviewnot_startedRecent-death rule: only what his doctors, his spokeswoman, his office, and he himself made public, with basic biographical facts from the Nelson Mandela Foundation. No statement or health fact is attributed to a relative or colleague.
safe messaging reviewnot_startedImprisonment and tuberculosis are recorded as history only, factually; no behavioral-health diagnosis; death recorded without detail.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.